424 related articles for article (PubMed ID: 37468932)
1. Early non-response as a predictor of later non-response to antipsychotics in schizophrenia: a randomized trial.
Long Y; Wu Q; Yang Y; Cai J; Xiao J; Liu Z; Xu Y; Chen Y; Huang M; Zhang R; Xu X; Hu J; Liu Z; Liu F; Zheng Y; Meng H; Wang Z; Tang Y; Song X; Chen Y; Wang X; Liu T; Wu X; Fang M; Wan C; Zhao J; Wu R
BMC Med; 2023 Jul; 21(1):263. PubMed ID: 37468932
[TBL] [Abstract][Full Text] [Related]
2. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
Johnsen E; Kroken RA; Løberg EM; Rettenbacher M; Joa I; Larsen TK; Reitan SK; Walla B; Alisauskiene R; Anda LG; Bartz-Johannessen C; Berle JØ; Bjarke J; Fathian F; Hugdahl K; Kjelby E; Sinkeviciute I; Skrede S; Stabell L; Steen VM; Fleischhacker WW
Lancet Psychiatry; 2020 Nov; 7(11):945-954. PubMed ID: 33069317
[TBL] [Abstract][Full Text] [Related]
3. Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics.
Chen YL; Chen KP; Chiu CC; Tai MH; Lung FW
BMC Psychiatry; 2018 Dec; 18(1):376. PubMed ID: 30509308
[TBL] [Abstract][Full Text] [Related]
4. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
Rosa F; Schreiner A; Thomas P; Sherif T
Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
[TBL] [Abstract][Full Text] [Related]
5. Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Tang Y; Wu Y; Li X; Hao Q; Deng W; Yue W; Yan H; Zhang Y; Tan L; Chen Q; Yang G; Lu T; Wang L; Yang F; Zhang F; Yang J; Li K; Lv L; Tan Q; Zhang H; Ma X; Li L; Wang C; Ma X; Zhang D; Yu H; Zhao L; Ren H; Wang Y; Zhang G; Li C; Du X; Hu X; Li T; Wang Q
Curr Neuropharmacol; 2023; 21(2):424-436. PubMed ID: 36411567
[TBL] [Abstract][Full Text] [Related]
6. Does drug use affect the efficacy of amisulpride, aripiprazole and olanzapine in patients with schizophrenia spectrum disorders? Results from a pragmatic, randomised study.
Alisauskiene R; Johnsen E; Gjestad R; Kroken RA; Kjelby E; Sinkeviciute I; Fathian F; Joa I; Reitan SK; Rettenbacher M; Løberg EM
Gen Hosp Psychiatry; 2023; 83():185-193. PubMed ID: 37269769
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
[TBL] [Abstract][Full Text] [Related]
8. Impact of childhood trauma on antipsychotic effectiveness in schizophrenia spectrum disorders: A prospective, pragmatic, semi-randomized trial.
Mørkved N; Johnsen E; Kroken RA; Winje D; Larsen TK; Thimm JC; Rettenbacher MA; Johannesen CAB; Løberg EM
Schizophr Res; 2022 Aug; 246():49-59. PubMed ID: 35709647
[TBL] [Abstract][Full Text] [Related]
9. Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.
Cai J; Li L; Shao T; Sun M; Wang W; Xie P; Wang X; Yang Y; Long Y; Kang D; Xiao J; Su Y; Peng X; Huang Y; Gao M; Wu Q; Song C; Liu F; Shao P; Ou J; Shen Y; Huang J; Wu R
Psychiatry Res; 2023 Apr; 322():115138. PubMed ID: 36871411
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole versus other atypical antipsychotics for schizophrenia.
Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
[TBL] [Abstract][Full Text] [Related]
11. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
12. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
13. Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.
Ganguli R; Brar JS; Mahmoud R; Berry SA; Pandina GJ
BMC Med; 2008 Jun; 6():17. PubMed ID: 18590519
[TBL] [Abstract][Full Text] [Related]
14. Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.
Schmidt-Kraepelin C; Feyerabend S; Engelke C; Riesbeck M; Meisenzahl-Lechner E; Verde PE; Correll CU; Kluge M; Makiol C; Neff A; Lange C; Englisch S; Zink M; Langguth B; Poeppl TB; Reske D; Gouzoulis-Mayfrank E; Gründer G; Hasan A; Brockhaus-Dumke A; Jäger M; Baumgärtner J; Leucht S; Cordes J;
Lancet Psychiatry; 2022 Apr; 9(4):291-306. PubMed ID: 35276079
[TBL] [Abstract][Full Text] [Related]
15. Clinical insight among persons with schizophrenia spectrum disorders treated with amisulpride, aripiprazole or olanzapine: a semi-randomised trial.
Stabell LA; Johnsen E; Kroken RA; Løberg EM; Blindheim A; Joa I; Reitan SK; Rettenbacher M; Munk-Jørgensen P; Gjestad R
BMC Psychiatry; 2023 Jun; 23(1):482. PubMed ID: 37386462
[TBL] [Abstract][Full Text] [Related]
16. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
[TBL] [Abstract][Full Text] [Related]
17. Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design.
Li X; Guo X; Fan X; Feng T; Wang C; Yao Z; Xu X; Chen Z; Wang H; Xie S; He J; Zhuo K; Xiang Q; Cen H; Wang J; Smith RC; Jin H; Keshavan MS; Marder SR; Davis JM; Jiang K; Xu Y; Liu D
Schizophr Res; 2021 Apr; 230():87-94. PubMed ID: 33279374
[TBL] [Abstract][Full Text] [Related]
18. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
19. Quantitative efficacy of three antipsychotic drugs for schizophrenia based on a real-world study in China.
Zhang L; Li YG; He S; Zhang Y; Yu YM; Li Y; Wen H; Qiao Y; Shen YF; Li HF
Acta Pharmacol Sin; 2019 Dec; 40(12):1611-1620. PubMed ID: 31388088
[TBL] [Abstract][Full Text] [Related]
20. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study.
Kahn RS; Winter van Rossum I; Leucht S; McGuire P; Lewis SW; Leboyer M; Arango C; Dazzan P; Drake R; Heres S; Díaz-Caneja CM; Rujescu D; Weiser M; Galderisi S; Glenthøj B; Eijkemans MJC; Fleischhacker WW; Kapur S; Sommer IE;
Lancet Psychiatry; 2018 Oct; 5(10):797-807. PubMed ID: 30115598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
